Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Evaluating Human Epidermal Growth Factor Receptor 2 Roles in the Efficacy of Tamoxifen Treatment in Breast Cancer, a Systematic Review Publisher Pubmed



Mansouri S1 ; Mokhtarihesari P2 ; Naghavialhosseini F1 ; Seyednejad SA1 ; Majidzadeha K1 ; Moradikalbolandi S1 ; Ghahremanlou M1 ; Farahmand L1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Recombinant Proteins Department, Breast Cancer Center, Motamed Cancer Institute, ACECR, Tehran, Iran
  2. 2. Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran

Source: Pharmacological Reports Published:2021


Abstract

Purpose: Hormone therapy with Tamoxifen is an effective treatment that can decrease recurrence rate and mortality. Numerous molecular mechanisms can modify the response to Tamoxifen. The objective of this study was to determine Tamoxifen efficacy on patients’ recurrence and mortality rates, according to the human epidermal growth factor receptor 2 (HER2) status. Methods: In this meta-analysis of published studies, relapse and death rates were measured in both HER2 negative and positive patients treated with Tamoxifen. Besides, the relative risk of treatment with Tamoxifen compared to no Tamoxifen treatment was evaluated in both HER2 positive and negative patients. Results: There was an increased risk of recurrence in HER2 positive patients who received Tamoxifen compared with HER2 negative ones (RR = 1.63, p value < 0.001). Tamoxifen treatment is associated with decreased relapse rate (RR = 0.70, p value < 0.001); however, it did not effect on HER2 positive ones (RR = 1, p value = 0.99). Conclusion: According to the analysis result, the relapse rate in breast cancer patients who were treated with Tamoxifen depends on the HER2 situation. Despite the limited sample size, it is revealed that Tamoxifen can decrease the relapse rate only in HER2 negative patients. © 2021, Maj Institute of Pharmacology Polish Academy of Sciences.
Related Docs
1. Challenges of Endocrine Therapy in Breast Cancer, Cancer Genetics and Psychotherapy (2017)
2. Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells May Be Induced by Interactions Between Receptor Tyrosine Kinases and Erα-66, Recent Patents on Anti-Cancer Drug Discovery (2018)
3. Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance Is Required, Current Cancer Drug Targets (2018)
4. A Review on the Role of Vegf in Tamoxifen Resistance, Anti-Cancer Agents in Medicinal Chemistry (2018)
5. Anti–Muc1 Nanobody Can Synergize the Tamoxifen and Herceptin Effects on Breast Cancer Cells by Inducing Er, Pr and Her2 Overexpression, International Immunopharmacology (2023)
6. Med1 May Explain the Interaction Between Receptor Tyrosine Kinases and Erα66 in the Complicated Network of Tamoxifen Resistance, European Journal of Pharmacology (2017)